Stephens analyst Sudan Loganathan lowered the firm’s price target on Immunome (IMNM) to $30 from $33 and keeps an Overweight rating on the shares. The firm updated estimates following the company’s Q4 business update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Immunome price target raised to $39 from $35 at JPMorgan
- Immunome: Buy Rating on Best-in-Class Varegacestat Opportunity and Differentiated Next-Generation ADC Oncology Platform
- Immunome reports FY25 EPS ($2.43), consensus ($2.21)
- Immunome: Advancing Best-in-Class Varegacestat and a Data-Driven ADC Pipeline Support Buy Rating and $40 Target
- Shopify upgraded, Coinbase downgraded: Wall Street’s top analyst calls